About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Cardiovascular Diseases group is a translational research group within the Cardiology Department of Vall d’Hebron Hospital that performs laboratory, clinical and epidemiological research. In the CIBERCV network we are within the topic of descriptor 2 “Arterial disease, thrombosis and myocardial ischemia-reperfusion injury”. Our contributions in these topics address the following lines:
In the CIBERESP network, our group is interested in the study of effectiveness/cost-effectiveness of cardiovascular interventions, health outcome research and methods in clinical research. The group has 19 principal investigators, 32 active projects and clinical trial and has been done 142 publications in 2020.
IP: José Raul Herance Camacho Collaborators: Sofia Rodriguez Fernandez, Sergi Velasco Vila, Clara Ramírez Serra, Azahara Maria Palomar Muñoz, Cristina Gamez Cenzano, Jana Vidal Otero, Carolina Aparicio Gomez, Alberto Roque Pérez, Mercè Abad Martín, Olga Simó Servat, Pedro Alejandro Gil Millán, Emily Betancourt Fernández, Martha Sahylí Ortega Pijeira, Maria Nazarena Pizzi, Enrique Franky Vargas Funding agency: Instituto de Salud Carlos III Funding: 252500 Reference: PI24/01356 Duration: 01/01/2025 - 31/12/2027
IP: Antonio Rodríguez Sinovas Collaborators: Elisabet Miro Casas, Gino Freddy Sena Ganse Funding agency: FUNDACIÓN ESPAÑOLA DE ARTERIOSCLEROSIS Funding: 15000 Reference: FEA/RODRIGUEZ/2024 Duration: 01/01/2025 - 31/12/2027
IP: Andrea Guala Collaborators: Ignacio Ferreira González, Pere López Gutierrez, Jose Fernando Rodríguez Palomares, Gisela Teixido i Tura, Juan Garrido Oliver, Lydia Dux-Santoy Hurtado, Laura Galián Gay Funding agency: Sociedad Española de Cardiologia Funding: 15000 Reference: SEC/GUALA/2024 Duration: 01/10/2024 - 31/12/2028
IP: Marisol Ruiz Meana Collaborators: - Funding agency: EUROPEAN COMMISSION Funding: Reference: EC / COST-ACTION / 2022 /RUIZ-MEANA Duration: 18/10/2023 - 17/10/2027
Women have a mortality rate of 21% during the 30 days following surgery, compared with 11% in men, a difference that remains after taking patients’ clinical characteristics into account.
The families of the professionals had the opportunity to visit the facilities and discover how we work at the institution.
The study, with the participation of VHIR, will analyse the physiological response of the human body thanks to data collected by smartwatches and wearable devices.
Echocardiography Rates
PDF 0.66 MB
Hemodynamics Rates
PDF 0.47 MB
